69 Year-Old Female Patient
Node: Negative
Size: 0.7 cm
Grade: 1
Case submitted by:
Debra Hutchins — Richmond, VA, USA
Patient Details
Menopausal status:
Post-Menopausal
Tumor type:
Lobular
Tumor size:
0.7 cm
ER status (IHC):
Positive
PR status (IHC):
Positive
HER2/NEU status:
Negative
Ki-67 status:
Histologic grade:
1
Lymph node status:
Negative
General health:
Asthma and thyroid dysfunction
Treatment given:
Lumptectomy, whole breast radiation, AI. Med onc recommended chemotherapy but patient declined, agreed to hormonal therapy
Other information
Exploratory Subgroup Analysis for TAILORx and NSABP B-20 indicate that Recurrence Score® and age are the strongest predictors of chemotherapy benefit1. The absolute reduction of distant recurrence from chemotherapy for patients >50 years and ≤50 years is shown here for RS groups: 11-15, 16-20, and 21-25 from TAILORx, and 0-10 and 26-100 from NSABP B-202.
Estimated Chemotherapy Benefit for Individual Recurrence Score Results
Recurrence Score ranges shown reflect randomized patients in NSABP B-20 and TAILORx.
1. Sparano et al. N Engl J Med. 2018.; ECOG and Genomic Health (data on file).
2. Paik et al. J Clin Oncol. 2006.; Sparano and Paik J Clin Oncol. 2008.
Order OncotypeDX® Online
To place an order online, visit our physician portal.
